Concepts (80)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2025 | 786 | 0.940 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.700 |
Why?
|
| Methotrexate | 4 | 2025 | 313 | 0.580 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2025 | 50 | 0.430 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2025 | 170 | 0.410 |
Why?
|
| Catheter-Related Infections | 2 | 2024 | 136 | 0.350 |
Why?
|
| Rhabdomyosarcoma | 2 | 2025 | 209 | 0.340 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 37 | 0.220 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2024 | 48 | 0.210 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2024 | 52 | 0.210 |
Why?
|
| Sarcoma, Kaposi | 1 | 2025 | 123 | 0.210 |
Why?
|
| Child | 14 | 2025 | 25062 | 0.210 |
Why?
|
| Health Information Systems | 1 | 2022 | 31 | 0.190 |
Why?
|
| Warfarin | 1 | 2023 | 112 | 0.190 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 51 | 0.190 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2022 | 26 | 0.180 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 52 | 0.180 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2022 | 63 | 0.180 |
Why?
|
| Wilms Tumor | 1 | 2023 | 116 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2025 | 1231 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1301 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2023 | 473 | 0.160 |
Why?
|
| Bayes Theorem | 1 | 2021 | 287 | 0.160 |
Why?
|
| Cross Infection | 1 | 2022 | 332 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2022 | 304 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 435 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2024 | 677 | 0.140 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 112 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 237 | 0.140 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1293 | 0.140 |
Why?
|
| Adolescent | 9 | 2025 | 19936 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 195 | 0.130 |
Why?
|
| Aortic Diseases | 1 | 2019 | 162 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 1163 | 0.120 |
Why?
|
| Child, Preschool | 6 | 2025 | 14329 | 0.110 |
Why?
|
| Aorta, Thoracic | 1 | 2019 | 465 | 0.110 |
Why?
|
| Age Factors | 1 | 2021 | 2772 | 0.110 |
Why?
|
| Thrombosis | 1 | 2019 | 501 | 0.110 |
Why?
|
| Humans | 16 | 2025 | 126089 | 0.100 |
Why?
|
| Malawi | 2 | 2025 | 310 | 0.100 |
Why?
|
| Infant | 5 | 2025 | 12762 | 0.090 |
Why?
|
| Young Adult | 4 | 2025 | 9616 | 0.080 |
Why?
|
| Anticoagulants | 2 | 2024 | 564 | 0.080 |
Why?
|
| Survival Rate | 2 | 2025 | 2060 | 0.070 |
Why?
|
| Risk Factors | 1 | 2021 | 10397 | 0.060 |
Why?
|
| Male | 7 | 2025 | 62089 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2025 | 16770 | 0.060 |
Why?
|
| Incidence | 2 | 2024 | 3213 | 0.060 |
Why?
|
| Prognosis | 2 | 2025 | 4709 | 0.060 |
Why?
|
| Oral Health | 1 | 2024 | 27 | 0.050 |
Why?
|
| Female | 6 | 2025 | 67915 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2024 | 157 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 197 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2023 | 45 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 65 | 0.050 |
Why?
|
| ADAM Proteins | 1 | 2022 | 83 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2022 | 41 | 0.050 |
Why?
|
| Machine Learning | 1 | 2025 | 320 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 102 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2023 | 171 | 0.040 |
Why?
|
| Recurrence | 1 | 2025 | 1400 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1187 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2022 | 571 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1216 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1281 | 0.040 |
Why?
|
| Heart Rate | 1 | 2022 | 567 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1350 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 457 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 203 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2019 | 202 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5050 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 4920 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1845 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 1098 | 0.020 |
Why?
|
| Time Factors | 1 | 2022 | 6016 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3680 | 0.020 |
Why?
|
| United States | 1 | 2022 | 11204 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2022 | 12328 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8358 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 30254 | 0.010 |
Why?
|